Cannabis Science, Inc. and Dana Farber Cancer Institute, Inc. Enter Into Historic Research Partnership

IRVINE, CA, May 20, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, has entered into a new Research Collaboration Agreement with Dana-Farber Cancer Institute, Inc. to investigate the potential use of a proprietary extract from the JusticiaRead More →

Nabiximols Improve Spasticity Symptoms in Motor Neuron Disease

From Neurology Advisor: Nabiximols, a cannabidiol, reduced spasticity symptoms and was tolerable and safe when used in patients with motor neuron disease, according to a phase 2 trial published in Lancet Neurology. In this randomized, double-blind study ( identifier: NCT01776970), patients with possible, probable, or definite amyotrophic lateral sclerosis orRead More →

Photo of Seattle Image Credit: Margaret Wallace. All Rights Reserved. Unauthorized Reuse Prohibited

In another historic first for advancing research into the uses of cannabis for pharmaceutical purposes, the University of Washington (UW) has entered into a deal with Canadian-based Pascal Biosciences. Negotiated by CoMotion, UW’s incubation group, the partnership involves UW licensing a cannabinoid-based compound, ST-403 (ST) for use in various pharma products.Read More →

Revive Therapeutics Granted FDA Orphan Drug Designation

According to a recent announcement made by Revive Therapeutics, the company has been granted an FDA Orphan Drug Designation for the use of cannabidiol (“CBD”) in preventing ischemia and reperfusion injury (“IRI”) — both of which can result from solid organ transplantation. Under the Orphan Drug Act of 1983, the FDARead More →

CBD-Derived Epidiolex Gains FDA Approval for Epilepsy

In an historic first, the U.S. Food and Drug Administration approved the drug Epidiolex for the treatment of children with epilepsy. The FDA-approved prescription of Epidiolex is specifically intended for the treatment of two kinds of very severe epilepsy, namely: Dravet  syndrome and Lennox-Gastaut Syndrome. GW Pharmaceuticals, based in the UK, manufactures theRead More →